Table 5 Completed and ongoing clinical trial of NK cell-based therapy for hematological malignancies
From: NK cell-based cancer immunotherapy: from basic biology to clinical development
Cancer type | Therapy | Phase | NCT | Status |
|---|---|---|---|---|
Acute myeloid leukemia | Allogeneic, IL-2 UCB-NK cells | I/II | NCT04347616 | Ongoing |
Allogeneic NK cell | I | NCT04220684 | Ongoing | |
Alloreactive NK cell | N/A | NCT03955848 | Ongoing | |
Poor prognosis non-AML hematologic malignancies | Allogeneic haploidentical NK cell infusions | I | NCT00697671 | Completed No outcome reported |
Refractory non-B lineage hematologic malignancies | Allogeneic haploidentical NK Cell Infusions | I | NCT00640796 | Completed No outcome reported |
CD33-positive acute myeloid leukemia | Anti-CD33 CAR-NK cells | I/II | NCT02944162 | PMID: 28054442 Found to be effective and prevented both tumor relapses and graft versus host disease |
Acute myeloid leukemia & advanced hematological malignancies | Alloreactive, IL-2 activated NK cells | I/II | NCT01220544 | Unknown No outcome reported |
Hematological malignancy patients who received fate therapeutics | Genetically modified NK cell | N/A | NCT04093622 | Ongoing |
High-risk tumor and lymphoma | Allogeneic haploidentical NK cell infusion combined with autologous stem cell transplantation | I | NCT02130869 | Completed No outcome reported |
Pediatric acute leukemia | Activated and expanded NK cells (NKAEs) | II | NCT02074657 | PMID: 29477379 Found to be safe and feasible |
Chronic Lymphocytic Leukemia (CLL) | NK cell with rituximab and Rhu-GMCSF | I | NCT00383994 | Completed No outcome reported |
NK cell | I | NCT02280525 | Ongoing | |
CD19 + Leukemia | Allogeneic anti-CD19 CAR-NK cells | I/II | NCT02892695 | PMID: 28054442 Found major improvements in treating leukemia |
Multiple myeloma | KIR-ligand mismatched NK cells from a haploidentical donor | I | NCT00089453 | Completed No outcome reported |
Acute myeloid leukemia & acute lymphoblastic leukemia | Expanded haploidentical NK cells | I | NCT04327037 | Ongoing |
Ph + acute lymphoblastic leukemia | Autologous NK cell | I | NCT02185781 | Unknown No outcome reported |
Lymphoma, myeloma, and leukemia | HLA-I haplotype mismatched NK cell | I | NCT00660166 | Completed No outcome reported |
Chronic myeloid leukemia | NK cell | I/II | NCT03348033 | Enrolling |
B cell non-Hodgkin’s lymphoma | Cord blood-derived expanded allogeneic NK cells combined with rituximab, high-dose chemotherapy, and stem cell transplant | II | NCT03019640 | Ongoing |
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells combined with high-dose chemotherapy and stem cell transplant | I/II | NCT03579927 | Withdrawn | |
B cell lymphoma | NK cells with rituximab | I/II | NCT02843061 | Completed No outcome reported |